Veracyte, Inc.
VCYTHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeVeracyte, Inc. operates as a diagnostics company in the United States and internationally. The company carries a $4.72B market cap, placing it firmly in the mid-cap category. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$4.72B
Beta
1.93
P/E (TTM)
54.75
P/E (Fwd)
30.94
EPS (TTM)
$1.08
EPS (Fwd)
$1.91
ROE
6.9%
ROA
3.8%
Cash
$439.1M
Total Debt
$39.3M
Free CF
$104.5M
52W Change
151.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $439.1M in cash comfortably exceeding the $39.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $104.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 6.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $296.5M (2022) to $517.1M (2025), reflecting a 74% increase over the period.
Veracyte, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, VCYT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VCYT.